Patents by Inventor Chuanfei JIN
Chuanfei JIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083870Abstract: Salts of pyridinylmethylenepiperidine derivatives and uses thereof including pharmaceutical composition including the salts, and uses of the salts and the pharmaceutical composition including the salts in the manufacture of a medicament for preventing, treating or lessening diseases related to 5-HT1F receptors, especially migraine in a patient.Type: ApplicationFiled: December 28, 2021Publication date: March 14, 2024Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Wenhe ZHONG, Tengfei XU
-
Publication number: 20240010643Abstract: A preparation method of substituted pyrimidine piperazine compounds, as well as intermediate compounds used in the method. The preparation method has the advantages of cheap and easily available raw materials, mild conditions, short reaction time, safety and controllability, high total yield, which is especially suitable for industrial production.Type: ApplicationFiled: September 16, 2021Publication date: January 11, 2024Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Haiping LIANG, Tengfei XU, Yingjun ZHANG
-
Patent number: 11858910Abstract: A pyridinylmethylenepiperidine derivatives and uses thereof, specifically, the present invention relates to a novel pyridinylmethylenepiperidine compound and a pharmaceutical composition containing this compound, which may be used for activating 5-HT1F receptor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a 5-HT1F receptor-related disease, especially migraine.Type: GrantFiled: August 22, 2019Date of Patent: January 2, 2024Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei Jin, Wenhe Zhong, Yaping Xue
-
Publication number: 20230312551Abstract: A salt of a 2-(substituted pyrimidinyl)thiazole carboxamide compound, and a composition and use thereof, and also a crystal form of the salt. Specifically, a pharmaceutical composition includes the salt, and a use of the salt or pharmaceutical composition in the preparation of a drug for preventing, treating or alleviating central nervous system dysfunction, particularly depression.Type: ApplicationFiled: June 29, 2021Publication date: October 5, 2023Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Tengfei XU, Huiqing YE
-
Publication number: 20230017597Abstract: An 8-substituted styryl xanthine derivatives and uses thereof, specifically, relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing this compound, which can be selective adenosine A2A receptor antagonist, and also relates to methods of preparing this compound and pharmaceutical composition, and uses thereof in the manufacture of a medicament for treating an adenosine A2A receptor-related disease, especially Parkinson's Disease.Type: ApplicationFiled: November 9, 2020Publication date: January 19, 2023Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Wenhe ZHONG, Tengfei XU
-
Publication number: 20220267347Abstract: Substituted pyrimidinedione compounds and uses thereof, as well as pharmaceutical compositions containing such compounds, which can be used as gonadotropin releasing hormone receptor antagonists and a method for preparing such compounds and pharmaceutical compositions and their uses in the prevention or treatment of sex hormone dependent diseases including but not limited to prostate cancer, endometriosis, hysteromyoma, precocious puberty and other diseases.Type: ApplicationFiled: July 28, 2020Publication date: August 25, 2022Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Wenhe ZHONG
-
Publication number: 20220202822Abstract: 8-substituted aryl vinyl xanthine derivatives and uses thereof, specifically, a novel class of 8-substituted aryl vinyl xanthine derivatives and pharmaceutical compositions containing these compounds, which can be selective adenosine A2A receptor antagonists. A method of preparing compounds and pharmaceutical compositions, and their uses in the manufacture of medicaments for treating an adenosine A2A receptor-related disease, especially Parkinson's Disease.Type: ApplicationFiled: April 18, 2020Publication date: June 30, 2022Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Wenhe ZHONG, Tengfei XU
-
Patent number: 11285153Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.Type: GrantFiled: September 21, 2018Date of Patent: March 29, 2022Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei Jin, Wenhe Zhong, Haiping Liang, Yingjun Zhang
-
Patent number: 11225460Abstract: A pyrrolidineamide derivatives and uses thereof, specifically, the present invention relates to a novel pyrrolidineamide compound and a pharmaceutical composition containing this compound, which can be used as a MAO-B inhibitor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a disease regulated by MAO-B comprising a neurodegenerative disease, especially Parkinson's disease.Type: GrantFiled: March 7, 2019Date of Patent: January 18, 2022Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei Jin, Kangzhi Chen, Yingjun Zhang
-
Publication number: 20210188803Abstract: A pyridinylmethylenepiperidine derivatives and uses thereof, specifically, the present invention relates to a novel pyridinylmethylenepiperidine compound and a pharmaceutical composition containing this compound, which may be used for activating 5-HT1F receptor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a 5-HT1F receptor-related disease, especially migraine.Type: ApplicationFiled: August 22, 2019Publication date: June 24, 2021Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Wenhe ZHONG, Yaping XUE
-
Publication number: 20210053918Abstract: A pyrrolidineamide derivatives and uses thereof, specifically, the present invention relates to a novel pyrrolidineamide compound and a pharmaceutical composition containing this compound, which can be used as a MAO-B inhibitor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a disease regulated by MAO-B comprising a neurodegenerative disease, especially Parkinson's disease.Type: ApplicationFiled: March 7, 2019Publication date: February 25, 2021Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei JIN, Kangzhi CHEN, Yingjun ZHANG
-
Publication number: 20200276196Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.Type: ApplicationFiled: September 21, 2018Publication date: September 3, 2020Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Chuanfei JIN, Wenhe ZHONG, Haiping LIANG, Yingjun ZHANG
-
Patent number: 10370380Abstract: The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease related to orexin receptors.Type: GrantFiled: November 23, 2016Date of Patent: August 6, 2019Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Chuanfei Jin, Ji Zhang
-
Patent number: 10316025Abstract: The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted piperazine compounds and pharmaceutical compositions comprising the compounds disclosed herein can be used for inhibiting 5-hydroxytryptamine reuptake and/or stimulating 5-HT1A receptors. The invention also relates to processes for preparing these compounds and pharmaceutical compositions, and their uses in the treatment of a central nervous system dysfunction.Type: GrantFiled: June 2, 2016Date of Patent: June 11, 2019Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Chuanfei Jin, Haiping Liang, Chao Yi, Ji Zhang
-
Patent number: 10196383Abstract: The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.Type: GrantFiled: July 14, 2016Date of Patent: February 5, 2019Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun Zhang, Chuanfei Jin, Jinheng Gao, Ji Zhang
-
Publication number: 20180334460Abstract: The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease related to orexin receptors.Type: ApplicationFiled: November 23, 2016Publication date: November 22, 2018Applicant: Sunshine Lake Pharma Co., Ltd.Inventors: Yingjun ZHANG, Chuanfei JIN, Ji ZHANG
-
Publication number: 20180215737Abstract: The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.Type: ApplicationFiled: July 14, 2016Publication date: August 2, 2018Applicant: Sunshine Lake Pharma Co., Ltd.Inventors: Yingjun ZHANG, Chuanfei JIN, Jinheng GAO, Ji ZHANG
-
Publication number: 20180179188Abstract: The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted piperazine compounds and pharmaceutical compositions comprising the compounds disclosed herein can be used for inhibiting 5-hydroxytryptamine reuptake and/or stimulating 5-HT1A receptors. The invention also relates to processes for preparing these compounds and pharmaceutical compositions, and their uses in the treatment of a central nervous system dysfunction.Type: ApplicationFiled: June 2, 2016Publication date: June 28, 2018Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yingjun ZHANG, Chuanfei JIN, Haiping LIANG, Chao YI, Ji ZHANG
-
Patent number: 9974785Abstract: Provided herein are aromatic heterocyclic derivatives or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof used for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.Type: GrantFiled: July 8, 2015Date of Patent: May 22, 2018Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Yingjun Zhang, Chuanfei Jin, Wenhe Zhong, Kangzhi Chen, Li Gao, Runzhi Liu, Ji Zhang
-
Patent number: 9840482Abstract: Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.Type: GrantFiled: April 20, 2015Date of Patent: December 12, 2017Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Yingjun Zhang, Chuanfei Jin, Wenhe Zhong, Hongpeng Xie, Ji Zhang